The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Persisting EGFR-mutant ctDNA may guide treatment selection in NSCLC
Martin Sebastian, MD, Goethe University Frankfurt, Frankfurt am Main, Germany, comments on the implications of persisting EGFR mutant circulating tumor DNA (ctDNA) as a prognostic biomarker in EGFR-mutant non-small cell lung cancer (NSCLC), highlighting that patients with this characteristic may not respond well to TKI monotherapy and may require alternative treatment approaches, such as TKI plus chemotherapy. Further analysis of specimens using next-generation sequencing (NGS) may help identify clusters and prognostic factors to guide treatment decisions. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
